Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

Inclusion criteria

include:

• Male and female patients aged 6 to 17 years, inclusive, who completed the 4-week study drug treatment in study OTR3001 and who, based on the investigator's judgment, will benefit from continuing treatment with oxycodone HCl CR 20 to 240 mg/day for the management of moderate to severe malignant or nonmalignant pain;
• Patients must have tolerated the oxycodone HCl CR therapy in OTR3001 as demonstrated at the start of the study;
• Patients must be willing and able to swallow the oxycodone HCl CR tablets whole.

Exclusion criteria

include:

• Patients with ongoing adverse events in OTR3001 that, in the investigator's opinion, disqualify them from participation in the study;
• Female patients who are pregnant or lactating;
• Patients requiring opioid at doses equivalent to < 20 mg/day or > 240 mg/day oxycodone for treatment of their malignant or nonmalignant pain;
• Patients who are allergic to oxycodone or have a history of allergies to other opioids (this criterion does not include patients who have experienced common opioid side effects [eg, nausea, constipation]);
• Patients who are contraindicated for the use of opioids;
• Patients who are currently being maintained on methadone for pain;
• Patients who have an abnormality on vital signs, physical examination, or laboratory testing significant enough that the investigator deems the patient is not appropriate for the study;
• Patients who have any planned surgery during the course of the study, with the exception of the placement of central or peripheral venous access devices;
• Patients currently taking an investigational medication/therapy other than the study drug (oxycodone HCl CR) at the start of screening or during the study.

Other protocol specific inclusion/exclusion criteria may apply.